Madrigal Pharma (MDGL)
537.65
-9.14 (1.67%)
Upcoming Events
Latest Headlines
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
July 21, 2026 4:05 PM - Globe NewsWire
Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results
July 17, 2026 5:02 AM - StreetInsider
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
July 16, 2026 8:00 AM - Globe NewsWire
Madrigal Pharmaceuticals receives three new resmetirom patents
July 13, 2026 8:03 AM - StreetInsider
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
July 13, 2026 8:00 AM - Globe NewsWire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
July 6, 2026 4:05 PM - Globe NewsWire
Ribo and Madrigal hit first milestone in siRNA MASH drug program
July 2, 2026 3:20 AM - StreetInsider
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
July 1, 2026 9:19 PM - PR NewsWire
Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
June 29, 2026 9:44 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
June 24, 2026 9:42 AM - StreetInsider
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
June 22, 2026 4:05 PM - Globe NewsWire
Madrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities
June 11, 2026 5:11 AM - StreetInsider
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
June 4, 2026 4:05 PM - Globe NewsWire
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
June 3, 2026 8:00 AM - Globe NewsWire
Madrigal Pharmaceuticals (MDGL) Reiterated at Market Outperform by Citizens
June 1, 2026 4:42 AM - StreetInsider
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
May 27, 2026 8:00 AM - Globe NewsWire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026 4:05 PM - Globe NewsWire
Madrigal to present Rezdiffra data at EASL 2026 conference
May 20, 2026 8:01 AM - StreetInsider
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
May 20, 2026 8:00 AM - Globe NewsWire
Madrigal Pharmaceuticals (MDGL) PT Raised to $709 at Truist Securities
May 13, 2026 6:16 AM - StreetInsider
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026 4:05 PM - Globe NewsWire
Madrigal Pharmaceuticals (MDGL) PT Lowered to $578 at Canaccord
May 7, 2026 6:39 AM - StreetInsider
Madrigal Pharma (MDGL) Tops Q1 EPS by 94c
May 6, 2026 7:08 AM - StreetInsider
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
May 6, 2026 7:00 AM - Globe NewsWire
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
May 5, 2026 8:03 AM - StreetInsider
Madrigal licenses siRNA asset from Arrowhead for MASH treatment
May 5, 2026 8:01 AM - StreetInsider
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
May 5, 2026 8:00 AM - Globe NewsWire
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026 8:00 AM - BizWire
Madrigal Pharmaceuticals (MDGL) PT Raised to $536 at BofA Securities
April 30, 2026 9:10 AM - StreetInsider
Full Article List
